Gil-de-Miguel, Ángel
Díez-Domingo, Javier
Martinón-Torres, Federico
Margüello, Esther Redondo
de Lejarazu Leonardo, Raúl Ortiz
Pumarola, Tomàs
de Sousa, Jaime Correia
Rabaçal, Carlos
Raposo, João
Cordeiro, Carlos Robalo
Froes, Filipe
Article History
Received: 16 February 2023
Accepted: 25 April 2023
First Online: 8 May 2023
Declarations
:
: The BARI study was conducted following the ethical principles of the Declaration of Helsinki and the local regulation, including privacy laws. The protocol of the BARI study was validated by a panel of clinical experts, classified by the Agency of Medicines and Medical Devices (AEMPS) as an observational study and approved by the Ethics Committee of Hospital Clinic de Barcelona (HCB/2020/1132). Informed consent to participate was waived by the same ethics committee that approved the study (Ethics Committee of Hospital Clinic de Barcelona).
: NA.
: Gil A, Díez-Domingo J, Rabaçal C, Raposo J, Robalo Cordeiro C, have received fees from Sanofi. Martinón Torres F received honoraria from GSK group of companies, Pfizer Inc, Sanofi, MSD, Seqirus, and Janssen for taking part in advisory boards and expert meetings and for acting as a speaker in congresses outside the scope of the submitted work. Martinón Torres F has also acted as principal investigator in randomized controlled trials of the above-mentioned companies as well as Ablynx, Gilead, Regeneron, Roche, Abbott, Novavax, and MedImmune, with honoraria paid to his institution. Martinón Torres F receives support for research activities from the Instituto de Salud Carlos III (Proyecto de Investigación en Salud, Acción Estratégica en Salud): Fondo de Investigación Sanitaria (FIS; PI070069 / PI1000540 / PI1601569 / PI1901090) del plan nacional de I + D + I and FEDER. Ortiz de Lejarazu R received honoraria from AstraZeneca, GSK, MSD, Roche, Sanofi and Seqirus for taking part in advisory boards and expert meetings and for acting as a speaker in congresses outside the scope of the submitted work. Ortiz de Lejarazu R has been until 2019 Director of the National Influenza Centre, Valladolid, Spain without any salary for that position and has participate in regular commitments of Influenza and other respiratory virus surveillance. Pumarola T Received honoraria from Roche, Sanofi, Seegene and Seqirus for taking part in advisory boards and expert meetings and for acting as a speaker in congresses outside the scope of the submitted work. Redondo Margüello E received honoraria from GSK group of companies, Pfizer Inc, Sanofi, and MSD, for taking part in advisory boards and expert meetings and for acting as a speaker in congresses outside the scope of the submitted work. Correia de Sousa J reports Advisory Board from Boehringer Ingelheim; personal fees and Advisory Board from GSK; grants, personal fees, and Advisory Board from AstraZeneca; personal fees and Advisory Board from Bial; non-financial support from Mundipharma; personal fees from Sanofi; Advisory Board from Novartis, outside the submitted work. Froes F reports Advisory Board and personal fees from Sanofi, Pfizer, MSD, Gilead and personal fees or non-financial support from Bial, AstraZeneca, GSK, Novartis, Boehringer Ingelheim, Tecnifar, Lilly, Bayer and Roche outside the submitted work.